Have a feature idea you'd love to see implemented?
Let us know!
NEO Neogenomics Inc
Price (delayed)
$13.57
Market cap
$1.74B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$1.99B
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose
Highlights
The company's EPS rose by 33% YoY and by 6% QoQ
The net income has grown by 32% YoY and by 7% from the previous quarter
The quick ratio has plunged by 73% from the previous quarter and by 67% YoY
The equity is down by 4.2% year-on-year
Key stats
What are the main financial stats of NEO
Market
Valuations
Earnings
Shares outstanding
128.16M
Market cap
$1.74B
Enterprise value
$1.99B
Price to book (P/B)
1.89
Price to sales (P/S)
2.73
EV/EBIT
N/A
EV/EBITDA
152.39
EV/Sales
3.17
Revenue
$628.25M
EBIT
-$69.19M
EBITDA
$13.06M
Free cash flow
-$29.73M
Per share
Balance sheet
Liquidity
EPS
-$0.62
Free cash flow per share
-$0.24
Book value per share
$7.17
Revenue per share
$4.97
TBVPS
$6.04
Total assets
$1.64B
Total liabilities
$727.39M
Debt
$606.52M
Equity
$915.88M
Working capital
$294.24M
Debt to equity
0.66
Current ratio
2.01
Quick ratio
1.84
Net debt/EBITDA
19.25
Margins
Efficiency
Dividend
EBITDA margin
2.1%
Gross margin
42.6%
Net margin
-12.5%
Operating margin
-15.2%
Return on assets
-4.7%
Return on equity
-8.4%
Return on invested capital
-7.7%
Return on capital employed
-5.1%
Return on sales
-11%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NEO stock price
How has the Neogenomics stock price performed over time
Intraday
0.37%
1 week
3.83%
1 month
-8%
1 year
-0.29%
YTD
-16.13%
QTD
-8%
Financial performance
How have Neogenomics's revenue and profit performed over time
Revenue
$628.25M
Gross profit
$267.86M
Operating income
-$95.28M
Net income
-$78.55M
Gross margin
42.6%
Net margin
-12.5%
NEO's net margin is up by 40% YoY and by 9% QoQ
Neogenomics's operating margin has increased by 36% YoY and by 10% from the previous quarter
The net income has grown by 32% YoY and by 7% from the previous quarter
The company's operating income rose by 27% YoY and by 8% QoQ
Growth
What is Neogenomics's growth rate over time
Valuation
What is Neogenomics stock price valuation
P/E
N/A
P/B
1.89
P/S
2.73
EV/EBIT
N/A
EV/EBITDA
152.39
EV/Sales
3.17
The company's EPS rose by 33% YoY and by 6% QoQ
The price to book (P/B) is 48% less than the 5-year quarterly average of 3.6 and 6% less than the last 4 quarters average of 2.0
The equity is down by 4.2% year-on-year
The price to sales (P/S) is 56% lower than the 5-year quarterly average of 6.2 and 9% lower than the last 4 quarters average of 3.0
The revenue rose by 14% YoY and by 2.9% QoQ
Efficiency
How efficient is Neogenomics business performance
The company's return on sales rose by 48% YoY and by 13% QoQ
NEO's ROIC is up by 31% year-on-year and by 2.5% since the previous quarter
The return on assets rose by 29% year-on-year and by 6% since the previous quarter
The return on equity has increased by 28% year-on-year and by 6% since the previous quarter
Dividends
What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NEO.
Financial health
How did Neogenomics financials performed over time
The total assets is 126% greater than the total liabilities
NEO's current ratio has plunged by 73% from the previous quarter and by 67% YoY
The quick ratio has plunged by 73% from the previous quarter and by 67% YoY
NEO's debt is 34% lower than its equity
The equity is down by 4.2% year-on-year
The debt to equity rose by 3.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.